Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial.

Major clinical research advances in gynecologic cancer in 2015. J Gynecol Oncol (2016) 0.81

Continuous HRT with oestrogen plus progestogen is linked to reduced risk of endometrial cancer. BMJ (2015) 0.75

Why women choose compounded bioidentical hormone therapy: lessons from a qualitative study of menopausal decision-making. BMC Womens Health (2017) 0.75

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37

The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med (2007) 12.23

Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA (2003) 10.61

Estrogen carcinogenesis in breast cancer. N Engl J Med (2006) 8.17

National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA (2004) 7.68

Implementation of the Women's Health Initiative study design. Ann Epidemiol (2003) 7.30

Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA (2013) 7.19

Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA (2010) 7.12

Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst (2007) 6.08

Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med (1975) 5.33

Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet (2005) 5.20

Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med (2009) 4.80

Progesterone induces adult mammary stem cell expansion. Nature (2010) 4.69

Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA (2008) 4.42

Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the U.S. Preventive Services Task Force recommendations. Ann Intern Med (2012) 4.17

The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause (2012) 4.04

Association of exogenous estrogen and endometrial carcinoma. N Engl J Med (1975) 3.89

Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA (2011) 3.85

Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol (2012) 3.56

Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA (2002) 3.13

Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA (2003) 2.90

Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA (1996) 2.90

Symptom experience after discontinuing use of estrogen plus progestin. JAMA (2005) 2.32

Type I and II endometrial cancers: have they different risk factors? J Clin Oncol (2013) 2.01

Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol (2005) 2.01

Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocr Rev (2013) 1.91

Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? Breast Cancer Res (2009) 1.75

Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev (2010) 1.75

Global consensus statement on menopausal hormone therapy. Climacteric (2013) 1.74

Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res (2000) 1.73

Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab (1999) 1.63

Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat (2007) 1.55

The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial. JAMA (1996) 1.54

Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses' Health Study cohort 1976-2004. Int J Cancer (2010) 1.52

Progesterone: the ultimate endometrial tumor suppressor. Trends Endocrinol Metab (2011) 1.46

The epidemiology of endometrial and ovarian cancer. Hematol Oncol Clin North Am (2011) 1.34

Case-control study of postmenopausal hormone replacement therapy and endometrial cancer. Am J Epidemiol (2006) 1.27

Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev (2012) 1.20

Biological roles of estrogen and progesterone in human endometrial carcinoma--new developments in potential endocrine therapy for endometrial cancer. Endocr J (2007) 1.20

Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev (2005) 1.19

Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. Int J Cancer (2011) 1.15

Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Am J Surg Pathol (2007) 1.13

Paradoxical clinical effect of estrogen on breast cancer risk: a "new" biology of estrogen-induced apoptosis. Cancer Prev Res (Phila) (2011) 1.09

Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk? Int J Cancer (2012) 1.07

Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition. Am J Epidemiol (2010) 1.06

Long-term postmenopausal hormone therapy and endometrial cancer. Cancer Epidemiol Biomarkers Prev (2010) 1.04

Impact of weight change and weight cycling on risk of different subtypes of endometrial cancer. Eur J Cancer (2013) 1.00

Declining incidence of breast cancer after decreased use of hormone-replacement therapy: magnitude and time lags in different countries. J Epidemiol Community Health (2011) 0.95

Recent changes in endometrial cancer trends among menopausal-age U.S. women. Cancer Epidemiol (2013) 0.91

Menopausal hormone therapy and risk of endometrial cancer. J Steroid Biochem Mol Biol (2013) 0.89

Catch it before it kills: progesterone, obesity, and the prevention of endometrial cancer. Discov Med (2012) 0.87

Long-term use of continuous-combined estrogen-progestin hormone therapy and risk of endometrial cancer. Cancer Causes Control (2011) 0.83

The contribution of postmenopausal hormone use cessation to the declining incidence of breast cancer. Cancer Causes Control (2010) 0.83

Risks of endometrial cancer associated with different hormone replacement therapies in the E3N cohort, 1992-2008. Am J Epidemiol (2014) 0.80

Fertility-sparing treatment of endometrial cancer: options, outcomes and pitfalls. J Gynecol Oncol (2012) 0.79